|
|
|
|
|
|
|
M Tue W Th F |
|
9 June, 2026 |
|
|
sponsored by
|
|
|
|
Secure Your Commercial Supply
|
| To support your commercial success, we're expanding our large-scale biologics drug product manufacturing capabilities, providing end-to-end solutions through our global network and enabling seamless integration of drug substance and drug product. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominations are open for our eighth annual Women in Biopharma report! It’s one of my favorite projects each year, because we get to profile 20 women who are reshaping the industry as we know it. Last year, for instance, Emma Walmsley reflected on her time running GSK. Nominations are due by July 10 via this form. If you have any questions, you can reach out to me at ndefeudis@endpoints.news. |
|
|
|
Nicole DeFeudis |
Senior Reporter, Endpoints News
@Nicole_DeFeudis
|
|
|
|
 |
|
Mathai Mammen, Parabilis Medicines CEO |
|
|
|
by Kyle LaHucik
|
Parabilis Medicines cemented the largest biotech IPO in industry history on Wednesday with its $670 million debut on the Nasdaq. But the Cambridge, MA-based drug... | |
|
|
|
|
|
|
by Max Bayer
|
Anxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug. The biotech... | |
|
|
|
|
|
 |
|
|
|
by Andrew Dunn
|
A dozen biotech executives took home nearly $1 billion worth of exit packages from selling their companies, an Endpoints News analysis found. The drug industry... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Novartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
SonoThera has secured $125 million to take its ultrasound-based gene therapy technology into the clinic. The company is focused on two lead programs in Duchenne... | |
|
|
|
|
|
